media – Page 104 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

J&J Adds Another Bispecific Antibody for Atopic Dermatitis With $1.25B Acquisition

Johnson & Johnson is acquiring a bispecific antibody that Numab Therapeutics engineered to address two pathways associated with the inflammation and itching of atopic dermatitis. It’s J&J’s second immunology acquisition this month. By Frank Vinluan Johnson & Johnson is building up its immunology pipeline, striking a $1.25 billion deal for a bispecific antibody in development for atopic dermatitis — its second acquisition agreement in the indication in the past two weeks. The deal announced Tuesday will bring J&J a Numab Therapeutics drug codenamed NM26. The pharmaceutical giant is acquiring global rights to the experimental treatment, which is ready to enter Phase 2 testing. Atopic dermatitis, also known as eczema, is the most common inflammatory skin disease. While the disorder typically presents as red and itchy skin, it stems from multiple pathways that vary from one group of patients to another. NM26 is a bispecific antibody designed to address two of ...
- Source: drugdu
- 106
- May 31, 2024
Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis

Don Tracy, Associate Editor The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion. Image Credit: Adobe Stock Images/Ityuan Johnson & Johnson (J&J) announced that it has agreed to terms with Numab Therapeutics to acquire its wholly owned subsidiary for the global rights to NM26, an investigational bispecific antibody currently in Phase II of development for the treatment of atopic dermatitis (AD). Under terms of the deal, J&J will pay Numab around $1.25 billion in an all-cash transaction. According to the company, the transaction is expected to close later this year, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of customary closing conditions. NM26 targets two established pathways, interleukin (IL)-4Rα and IL-31, in AD. According to investigators, this works by targeting IL-4Rα, which is responsible for Th2-mediated skin inflammation, and IL-31, which triggers skin itch and exacerbates AD. Additionally, NM26 has demonstrated ...
- Source: drugdu
- 75
- May 31, 2024
Entod Pharma launches Vitamin D3 eye drops

Entod Pharmaceuticals has launched Vitamin D3 enriched lubricating eye drops. These novel formulations aim to benefit ocular health, providing targeted relief for individuals suffering from dry eyes. Vitamin D3 has now been incorporated into some of Entod’s selected lubricant eye drop brands that are currently prescribed by eye doctors for dry eyes. Dry eye syndrome is a prevalent condition characterised by discomfort, irritation, and even vision impairment. The main causes of dry eyes are environmental factors, Vitamin deficiencies, Poor blinking habits, Contact lenses, Digital devices, Smoking, Refractive surgeries and more. Commenting on the launch, Nikkhil K Masurkar, CEO, Entod said, “ Adding Vitamin D3 to routine dry eye treatment improves ocular surface hemostasis parameters, results in better tear stability, improves tear osmolarity, and helps modulate corneal wound healing. Vitamin D3 enriched lubricating eye drops would only be available through health care professional prescriptions.” Emphasising the significance of Vitamin D on ...
- Source: drugdu
- 75
- May 31, 2024
Glenmark creates mass awareness around Hypertension

Glenmark Pharmaceuticals, marked the month of May as the ‘Hypertension Awareness Month’ by reportedly partnering with more than 1000 healthcare professionals (HCPs) from 250+ cities and towns across the country, and organised 400+ public awareness rallies and screening camps to create mass awareness around Hypertension (High Blood Pressure). The rallies consisted of general informative sessions led by HCPs, who provided detailed insights on the signs, symptoms, and preventive measures related to Hypertension. Subsequently, blood pressure screening camps were set up to offer the general public an opportunity to assess their blood pressure levels. Reportedly, as a result of this initiative, Glenmark successfully reached out to 6 million adults, effectively raising awareness about the disease. Hypertension, a prevalent cardiovascular disease (CVD) risk factor, affects approximately 35.5 per cent of adults in India. Alarmingly, CVD is the leading cause of death in the country, responsible for almost one-fourth of all mortality cases. ...
- Source: drugdu
- 80
- May 31, 2024
FDA grants priority review to Genentech’s Inavolisib

Genentech, a member of the Roche Group, announced that the USFDA has accepted the company’s new drug application and granted priority review to inavolisib, an investigational oral therapy, in combination with palbociclib (Ibrance) and fulvestrant. The inavolisib-based regimen was evaluated in adult patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. The priority review is based on the positive Phase III INAVO120 results, which showed the inavolisib-based regimen more than doubled progression-free survival, reducing the risk of disease worsening or death by 57 per cent compared to palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43, 95 per cent CI: 0.32-0.59, p<0.0001) in the first-line setting. Overall survival (OS) data were immature at the time of primary analysis, but a clear positive trend was observed ...
- Source: drugdu
- 83
- May 31, 2024
Merck KGaA announces its largest investment in Asia

Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea. The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies. Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies. The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
- Source: drugdu
- 86
- May 31, 2024
New AI Transparency Rule Should Drive Higher Quality Tools & More AI Adoption

Micky Tripathi, head of The Office of the National Coordinator for Health Information Technology (ONC), thinks his office’s recent rule on AI transparency will do a good job of empowering both providers and tech developers. “I think it’s going to spur more adoption of AI-based tools in healthcare delivery, and hopefully, it’s going to establish a sort of mechanism for driving higher quality AI-based tools,” he stated during an interview this month at the Reuters Digital Health conference in San Diego. In December, the ONC finalized a new rule that instated transparency requirements for the use of AI in healthcare settings. It requires healthcare AI developers to provide more data about their products to customers, which could aid providers in determining AI tools’ risks and effectiveness. Under the new rule, AI vendors must share information about how their software works and how it was developed. That means disclosing information about ...
- Source: drugdu
- 116
- May 30, 2024
Study reveals pivotal role of the circadian clock in enhancing checkpoint inhibitor cancer therapy

A multidisciplinary research team at the University of California, Irvine has revealed that the circadian clock – the biological pacemaker that governs daily rhythms in physiological processes, including immune functions – can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy. Checkpoint inhibitors block different proteins from binding to tumor cells, allowing the immune system’s T cells to kill the tumor. The study, published online today in the journal Nature Immunology, provides deeper insights into the intricate relationship among the circadian clock, immune regulation and tumor development and found that a therapeutic approach optimizing time-of-day delivery based on an individual’s unique circadian patterns offers new avenues for prevention and treatment. Selma Masri, corresponding author, UC Irvine associate professor of biological chemistry, said, “Disruption of the internal biological pacemaker is an inherent aspect of modern society that may contribute to the rising incidence of many cancer types. We found ...
- Source: drugdu
- 129
- May 30, 2024
Insmed’s Trial Results Pave Way for FDA Filing in a Lung Disease With No Approved Therapies

Brensocatib, a drug Insmed licensed from AstraZeneca, met the main goal of a Phase 3 test in non-cystic fibrosis bronchiectasis. Insmed plans to seek regulatory approvals in this indication while also continuing to develop the small molecule for other inflammatory disorders. By Frank VinluanAn Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a regulatory submission planned for later this year. It could be the first of several. The drug is also in development for other inflammatory conditions, giving the drug multiple opportunities to achieve its blockbuster potential. The first disease target of the Insmed drug is non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease characterized by excess production of sputum that’s persistently coughed up from the respiratory tract. Patients who have NCFB also experience frequent respiratory infections. There’s no ...
- Source: drugdu
- 98
- May 30, 2024
FDA Grants Fast Track Designation to AV-001 for Moderate-to-Severe Acute Respiratory Distress Syndrome

Don Tracy, Associate Editor Fast track designation for AV-001 comes amid promising results from a Phase I trial, which supported once-daily dosing and effective Tie2 activation. Vasomune Therapeutics announced that the FDA has granted Fast Track designation to AV-001, an investigational drug in development to prevent or treat moderate-to-severe acute respiratory distress syndrome (ARDS) in patients with respiratory infections. According to the company, Phase I data demonstrated the safety and pharmacokinetic profile of AV-001, backing once-daily dosing. Additionally, the treatment showed support for strong Tie2 activation. AV-001 is currently recruiting patients for a Phase IIa trial as an ARDS treatment in pneumonia.1 “Vasomune is focused on the persisting unmet needs of people grappling with ARDS and other diseases driven by vascular endothelial instability,” said Brian Jahns, PharmD, president, chief operating officer, Vasomune Therapeutics, in a press release. “Vasomune is indebted to the United States Department of Defense Congressionally Directed Medical ...
- Source: drugdu
- 90
- May 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.